A Chinese parallel design, randomized clinical trial showed that the incidence of major cardiovascular events among patients with type 2 diabetes (T2D) was significantly lower with intensive treatment targeting a systolic blood pressure (SBP) of less than 120 mm Hg than with standard treatment targeting a SBP of less than […]
An open-cluster randomized clinical trial in China showed that a nonphysician community health care practitioner–led, multifaceted, intensive blood pressure (BP) intervention was effective and safe in younger and older individuals with high BP. From 2018 to 2023, 22 386 and 11 609 individuals (mean age 63.0 years, females 61.3%) 60 years and […]
A systematic review and network meta-analysis, which allowed the simultaneous comparison of multiple achieved systolic blood pressure (SBP) levels on clinical outcomes while preserving trial-level treatment randomization, indicates that treating patients to reduce SBP below currently recommended targets may significantly reduce risk of cardiovascular disease (CVD) and all-cause mortality, with […]